FIELD: biotechnology.
SUBSTANCE: invention relates to heterodimeric Fc fusion proteins. Disclosed are heterodimeric Fc fusion proteins for inducing T-cell proliferation, in which Fc domains contain modifications facilitating their heterodimerisation. Invention provides producing IL-12 heterodimer in form of fused proteins with Fc with enhanced circulation in blood, in which to eliminate antagonist action of subunit IL-12p40 formed preliminary complex of subunits IL-12p40 and IL-12p35, and also reduced activity of IL-12 variants for improving pharmacokinetics and therapeutic index.
EFFECT: invention can be used to induce reproduction of T-cells.
24 cl, 67 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN 12 AND METHODS OF USE THEREOF | 2019 |
|
RU2826183C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
| COMPOSITION FOR CULTURING NATURAL KILLER CELLS AND METHOD OF PRODUCING NATURAL KILLER CELLS USING SAME | 2020 |
|
RU2824216C1 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
